- Home
- PBYI
as of 12-05-2025 3:42pm EST
$5.27
$0.02
-0.38%
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Chart Type:
Time Range:
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | LOS ANGELES |
| Market Cap: | 263.4M | IPO Year: | N/A |
| Target Price: | $7.00 | AVG Volume (30 days): | 637.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.74 | EPS Growth: | 59.87 |
| 52 Week Low/High: | $2.58 - $6.12 | Next Earning Date: | 11-06-2025 |
| Revenue: | $211,995,000 | Revenue Growth: | -12.96% |
| Revenue Growth (this year): | -1.86% | Revenue Growth (next year): | -0.57% |
AI-Powered PBYI Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 67.55%
67.55%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Puma Biotechnology Inc (PBYI)
MILLER MICHAEL PATRICK
Sell
Director
PBYI Nov 11, 2025
Avg Cost/Share
$4.86
Shares
20,000
Total Value
$97,228.00
Owned After
54,000
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| MILLER MICHAEL PATRICK | PBYI | Director | Nov 11, 2025 | Sell | $4.86 | 20,000 | $97,228.00 | 54,000 |
Latest Puma Biotechnology Inc News
PBYI Breaking Stock News: Dive into PBYI Ticker-Specific Updates for Smart Investing
Simply Wall St.
Stabilis Solutions And 2 Other Noteworthy Penny Stocks
📊
AI Sentiment
Positive
7/10
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
📊
AI Sentiment
Positive
7/10
Simply Wall St.
Promising Penny Stocks To Watch In December 2025
Simply Wall St.
With 60% ownership of the shares, Puma Biotechnology, Inc. (NASDAQ:PBYI) is heavily dominated by institutional owners
📊
AI Sentiment
Positive
6/10
Compare PBYI vs Leading Stocks
See how PBYI stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PBYI Puma Biotechnology Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.